Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment


Creative Commons License

Alp E., Damkaci F., GÜVEN E., Tenniswood M.

INTERNATIONAL JOURNAL OF NANOMEDICINE, vol.14, pp.1335-1346, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14
  • Publication Date: 2019
  • Doi Number: 10.2147/ijn.s191837
  • Journal Name: INTERNATIONAL JOURNAL OF NANOMEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1335-1346
  • Keywords: cell cycle, apoptosis, DNA fragmentation, gene expression, epigenetics, MCF-7, SOLID LIPID NANOPARTICLES, DRUG-DELIVERY, POLYMERIC NANOPARTICLES, TRICHOSTATIN-A, CELL-CYCLE, APOPTOSIS, LIPOSOMES, GENE, NANOSPHERES, EXPRESSION
  • Hacettepe University Affiliated: Yes

Abstract

Background: The efficacy of epigenetic drugs, such as histone deacetylase inhibitors, is often diminished by poor aqueous solubility resulting in limited bioavailability and a low therapeutic index. To overcome the suboptimal therapeutic index, we have developed a biocompatible starch nanoparticle formulation of CG-1521, a histone deacetylase inhibitor in preclinical development for hard-to-treat breast cancers, which improves its bioavailability and half-life.